4-(3,4-dimethoxyphenyl)-2-phenyl-1H-imidazole | 1204141-45-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 4-(3,4-dimethoxyphenyl)-2-phenyl-1H-imidazole
• 英文别名: 2-phenyl-4-(3',4'-dimethoxyphenyl)imidazole；4-(3,4-dimethoxyphenyl)-2-phenylimidazole；5-(3,4-dimethoxyphenyl)-2-phenyl-1H-imidazole
• CAS: 1204141-45-6
• 化学式: C₁₇H₁₆N₂O₂
• 分子量: 280.326
• InChiKey: JJBBNIPDRYUCIX-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.3
• 重原子数：
  21
• 可旋转键数：
  4
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  47.1
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  4-(3,4-dimethoxyphenyl)-2-phenyl-1H-imidazole 在 三溴化硼 、 甲醇 作用下， 以 二氯甲烷 为溶剂， 以85%的产率得到4-(3,4-dihydroxyphenyl)-2-phenylimidazole hydrobromide
  参考文献：
  名称：

  [EN] NEW DRUG FOR INHIBITING AGGREGATION OF PROTEINS INVOLVED IN DISEASES LINKED TO PROTEIN AGGREGATION AND/OR NEURODEGENERATIVE DISEASES
  [FR] NOUVEAU MÉDICAMENT POUR L'INHIBITION DE L'AGRÉGATION DES PROTÉINES IMPLIQUÉES DANS DES MALADIES ASSOCIÉES À L'AGRÉGATION DES PROTÉINES ET/OU DES MALADIES NEURODÉGÉNÉRATIVES

  摘要：

  公开号：

  WO2010000372A3
• 作为产物：
  描述：

  溴代-3,4-二甲氧基苯乙酮 、 苄脒盐酸盐 在 碳酸氢钠 作用下， 以 四氢呋喃 、 水 为溶剂， 反应 2.5h， 以84%的产率得到4-(3,4-dimethoxyphenyl)-2-phenyl-1H-imidazole
  参考文献：
  名称：

  [EN] NEW DRUG FOR INHIBITING AGGREGATION OF PROTEINS INVOLVED IN DISEASES LINKED TO PROTEIN AGGREGATION AND/OR NEURODEGENERATIVE DISEASES
  [FR] NOUVEAU MÉDICAMENT POUR L'INHIBITION DE L'AGRÉGATION DES PROTÉINES IMPLIQUÉES DANS DES MALADIES ASSOCIÉES À L'AGRÉGATION DES PROTÉINES ET/OU DES MALADIES NEURODÉGÉNÉRATIVES

  摘要：

  公开号：

  WO2010000372A3

文献信息

• Imidazoles from nitroallylic acetates and α-bromonitroalkenes with amidines: synthesis and trypanocidal activity studies
  作者：Elumalai Gopi、Tarun Kumar、Rubem F. S. Menna-Barreto、Wagner O. Valença、Eufrânio N. da Silva Júnior、Irishi N. N. Namboothiri

  DOI：10.1039/c5ob01444a

  日期：——

  Cascade reactions of amidines with nitroallylic acetates and α-bromonitroalkenes provide potentially bioactive imidazoles in good to excellent yields in most cases. While 2,4-disubstituted imidazol-5-yl acetates are formed in the first case, 2,4-disubstituted imidazoles, bearing no substituent at position 5, are the products in the second case. These two series of imidazoles, viz. 2,4,5-trisubstituted

  在大多数情况下，am与乙酸烯丙酯和α-溴硝基烯烃的级联反应可提供潜在的具有生物活性的咪唑，其收率良好至极佳。在第一种情况下形成2,4-二取代的咪唑-5-基乙酸盐，而在第二种情况下形成2,4-二取代的咪唑，它们在5位不带取代基。这两个咪唑系列，即。筛选了2,4,5-三取代和2,4-二取代的抗原生动物寄生虫克氏锥虫的活性，锥虫是南美锥虫病的病因。多达三种化合物的活性与标准苯并咪唑一样，而另外两种化合物的活性则高2–3倍，这突出了取代的咪唑的潜力，它很容易从硝基烯烃中获得，并可能是抗寄生虫药。
• NEW DRUG FOR INHIBITING AGGREGATION OF PROTEINS INVOLVED IN DISEASES LINKED TO PROTEIN AGGREGATION AND/OR NEURODEGENERATIVE DISEASES
  申请人：Giese Armin

  公开号：US20110293520A1

  公开（公告）日：2011-12-01

  The present invention relates to a compound represented by formula (E). The present invention also relates to a compound represented by the formula (E) for use in the treatment or prevention of diseases linked to protein aggregation and/or neurodegenerative diseases. Moreover, the present invention relates to pharmaceutical and diagnostic compositions comprising the compound of the invention as well as to a kit. Furthermore, the present invention relates to a method of imaging deposits of aggregated protein. A kit for preparing a detectably labelled compound of the present invention is also disclosed. Formula (E) wherein X, Y and L are independently nondirectionally selected from —C(R 1 )(R 2 )—, —C(R 3 )═, —N(R 4 )—, —N═, —N + (R 5 )═, —O— and —S—; M and Z are independently nondirectionally selected from formula (I) and formula (II).

  本发明涉及一种由公式（E）表示的化合物。本发明还涉及一种由公式（E）表示的化合物，用于治疗或预防与蛋白质聚集和/或神经退行性疾病相关的疾病。此外，本发明涉及包含本发明化合物的制药和诊断组合物，以及一种试剂盒。此外，本发明还涉及一种成像聚集蛋白沉积物的方法。还公开了一种用于制备可检测标记的本发明化合物的试剂盒。公式（E）中，X、Y和L分别独立地从—C（R1）（R2）—、—C（R3）═、—N（R4）—、—N═、—N+（R5）═、—O—和—S—中非定向选择；M和Z分别独立地从公式（I）和公式（II）中非定向选择。
• DRUG FOR INHIBITING AGGREGATION OF PROTEINS INVOLVED IN DISEASES LINKED TO PROTEIN AGGREGATION AND/OR NEURODEGENERATIVE DISEASES
  申请人：Ludwig-Maximilians-Universität München

  公开号：US20160185730A1

  公开（公告）日：2016-06-30

  The present invention relates to a compound represented by formula (E). The present invention also relates to a compound represented by the formula (E) for use in the treatment or prevention of diseases linked to protein aggregation and/or neurodegenerative diseases. Moreover, the present invention relates to pharmaceutical and diagnostic compositions comprising the compound of the invention as well as to a kit. Furthermore, the present invention relates to a method of imaging deposits of aggregated protein. A kit for preparing a detectably labelled compound of the present invention is also disclosed.

  本发明涉及一种由式(E)所表示的化合物。本发明还涉及一种由式(E)所表示的化合物，用于治疗或预防与蛋白质聚集和/或神经退行性疾病有关的疾病。此外，本发明还涉及包含本发明化合物的制药和诊断组合物，以及一种试剂盒。此外，本发明还涉及一种成像聚集蛋白沉积物的方法。还公开了一种用于制备本发明化合物的可检测标记试剂盒。
• Drugs for inhibiting aggregation of proteins invoved in diseases linked to protein aggregation and/or neurodegenerative diseases
  申请人：Ludwig-Maximilians-Universität München

  公开号：EP2687513A1

  公开（公告）日：2014-01-22

  The present invention relates to a compound represented by formula (E). The present invention also relates to a compound represented by the formula (E) for use in the treatment or prevention of diseases linked to protein aggregation and/or neurodegenerative diseases. Moreover, the present invention relates to pharmaceutical and diagnostic compositions comprising the compound of the invention as well as to a kit. Furthermore, the present invention relates to a method of imaging deposits of aggregated protein. A kit for preparing a detectably labelled compound of the present invention is also disclosed.

  本发明涉及一种由式（E）代表的化合物。本发明还涉及一种由式（E）代表的化合物，用于治疗或预防与蛋白质聚集相关的疾病和/或神经退行性疾病。此外，本发明还涉及包含本发明化合物的药物和诊断组合物以及试剂盒。此外，本发明还涉及一种对聚集蛋白沉积物成像的方法。本发明还公开了一种用于制备可检测标记的本发明化合物的试剂盒。
• Drug for inhibiting aggregation of proteins involved in diseases linked to protein aggregation and/or neurodegenerative diseases
  申请人：Ludwig-Maximilians-Universität München

  公开号：US10071966B2

  公开（公告）日：2018-09-11

  The present invention relates to a compound represented by formula (E). The present invention also relates to a compound represented by the formula (E) for use in the treatment or prevention of diseases linked to protein aggregation and/or neurodegenerative diseases. Moreover, the present invention relates to pharmaceutical and diagnostic compositions comprising the compound of the invention as well as to a kit. Furthermore, the present invention relates to a method of imaging deposits of aggregated protein. A kit for preparing a detectably labelled compound of the present invention is also disclosed.

  本发明涉及一种由式（E）代表的化合物。本发明还涉及一种由式（E）代表的化合物，用于治疗或预防与蛋白质聚集相关的疾病和/或神经退行性疾病。此外，本发明还涉及包含本发明化合物的药物和诊断组合物以及试剂盒。此外，本发明还涉及一种对聚集蛋白沉积物成像的方法。本发明还公开了一种用于制备可检测标记的本发明化合物的试剂盒。